Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

INTRODUCTION: Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved worldwide for the treatment of patients with type 2 diabetes mellitus (T2DM). The present study evaluated pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with T2DM. METHODS: Canag...

Descripción completa

Detalles Bibliográficos
Autores principales: Iijima, Hiroaki, Kifuji, Takayuki, Maruyama, Nobuko, Inagaki, Nobuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569680/
https://www.ncbi.nlm.nih.gov/pubmed/26280756
http://dx.doi.org/10.1007/s12325-015-0234-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569680/
https://www.ncbi.nlm.nih.gov/pubmed/26280756
http://dx.doi.org/10.1007/s12325-015-0234-0

Ejemplares similares